ALFA Filings
Every announcement, straight from the exchange
Every Piramal Pharma other announcement announcement on NSE and BSE, newest first, each with its own page.
Time
6 announcements with these filters
The company filed its quarterly shareholding pattern for the period ended September 30, 2026. The report details equity distribution among promoters and public shareholders.
Piramal Pharma Limited informed exchanges that Niche99 has independently assigned it an ESG rating of 67.1 (ESG Band: Leader), without any company engagement.
Piramal Pharma Limited received an improved ESG rating of 65 from NSE Sustainability Ratings and Analytics. The rating was assigned voluntarily based on public disclosures.
Piramal Pharma Ltd has submitted its quarterly shareholding pattern for the period ended June 30, 2026, in compliance with SEBI regulations.
Piramal Pharma submitted its Annual Secretarial Compliance Report for the financial year 2025-26. The report confirms adherence to SEBI regulations with no adverse observations noted.
Piramal Pharma Limited has updated the contact details for its Key Managerial Personnel (KMP) under SEBI Regulation 30(5). CFO Vivek Valsaraj and Company Secretary Maneesh Sharma are authorized for determining materiality and making stock exchange disclosures.